Genentech Reports Positive Phase II Results for Petrelintide in Obesity Trial
Genentech announced positive Phase II results for petrelintide, showing up to 10.7% mean weight loss versus 1.7% placebo at week 42 in people with overweight and obesity, with placebo-like tolerability.
Genentech, a member of the Roche Group, announced positive topline results from the Phase II ZUPREME-1 trial evaluating investigational petrelintide versus placebo in 493 people living with overweight and obesity in a gender-balanced trial population. The study met its primary endpoint, demonstrating that once-weekly subcutaneous injections of petrelintide resulted in statistically significant and clinically meaningful weight loss from baseline after 28 weeks in all five treatment arms compared to placebo.
Petrelintide achieved up to 10.7% mean body weight reduction at week 42 versus 1.7% with placebo (p-value<0.001) while demonstrating placebo-like tolerability. The weight loss was sustained through week 42 with participants achieving up to 10.7% mean weight loss from baseline using the efficacy estimand, compared to 1.7% with placebo.
The trial enrolled participants with a mean BMI of 37 kg/m². Petrelintide was administered via once-weekly subcutaneous injections, escalated every fourth week. In the cohort that achieved the greatest reduction in body weight, 98% of trial participants treated with petrelintide reached the maintenance dose underscoring its favorable tolerability profile. Body weight reduction using the treatment regimen estimand was largely consistent with the efficacy estimand.
At the maximally effective dose, there were no cases of vomiting and no treatment discontinuations due to gastrointestinal adverse events. Female participants lost considerably more weight than male participants in this trial.
The data support further development of petrelintide in chronic weight management as monotherapy and its tolerability profile also confirms its value as a combination partner.